MedPath

Feasibility study of adjuvant chemotherapy with nanoparticle albumin-bound (nab)- paclitaxel and carboplatin in patients with completely resected pathological IB non small cell lung cancer

Not Applicable
Recruiting
Conditions
on-small cell lung cancer
Registration Number
JPRN-UMIN000011215
Lead Sponsor
Department of Thoracic Surgery , Faculty of Life Science Kumamoto University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
35
Inclusion Criteria

Not provided

Exclusion Criteria

1)Anamnesis of hypersensitivity to drugs 2)Massive pleural or pericardial effusion 3)With active double cancer 4)Severe complication (ileus , interstitial pneumonia , interstitial pneumonia , pulmonary fibrosis, uncontrolled diabetes , heart failure , renal failure, hepatic failure, and so on) 5) With active infections 6) With a difficult bowel movement 7) Pleural effusion, cardiac effusion, or cardiac effusion necessitating treatment. 8) Pregnancy or lactating patients 9) Uncontrolled psychiatric disease 10)With poor-controlled diabetes mellitus 11) Concurrent steroid therapy 12) With HBs or HCV 13) With HIV 14) Physician judged improper to entry this trial

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The completion rate of four cycles
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath